Raloxifene 60 mg Tablet

Raloxifene ( Raloxiheal )  60 mg Tablet – Generic Evista | FDA-Approved SERM for Osteoporosis and Breast Cancer Risk Reduction

Raloxifene 60 mg Tablet is a prescription-only, orally administered second-generation Selective Estrogen Receptor Modulator (SERM) and the generic equivalent of Evista, originally developed and marketed by Eli Lilly and Company. First approved by the FDA in 1997 for the prevention of postmenopausal osteoporosis, expanded in 1999 for its treatment, and further approved in 2007 for the reduction of invasive breast cancer risk, Raloxifene 60 mg has over two decades of clinical validation and remains one of the most prescribed SERMs for postmenopausal women worldwide.

Generic Raloxifene 60 mg tablets are manufactured by several WHO-GMP certified pharmaceutical companies including Healing Pharma, and are available globally at significantly lower cost than branded Evista while delivering identical clinical efficacy and bioequivalence.

Raloxifene 60 mg works through a unique dual mechanism — acting as an estrogen agonist in bone and liver while simultaneously functioning as an estrogen antagonist in breast and uterine tissue. This tissue selectivity makes it one of the most clinically precise hormonal agents available, delivering the bone-protective benefits of estrogen without the associated risks of breast stimulation, endometrial hyperplasia, or uterine cancer.

What is Raloxifene 60 mg Used For?

Treatment and Prevention of Postmenopausal Osteoporosis

Osteoporosis is the primary FDA-approved indication for Raloxifene 60 mg. After menopause, declining estrogen levels cause bone resorption to outpace bone formation — resulting in progressive loss of bone mineral density, increased skeletal fragility, and significantly elevated fracture risk. Raloxifene acts as an estrogen agonist in bone tissue, inhibiting accelerated bone resorption, preserving bone mineral density, and reducing the risk of vertebral fractures. In the landmark MORE (Multiple Outcomes of Raloxifene Evaluation) trial involving over 7,700 postmenopausal women, Raloxifene 60 mg reduced the incidence of vertebral fractures by 30 to 50% compared to placebo. It is indicated both for women who have already developed osteoporosis and for those at risk of developing it following menopause. Supplemental calcium (1,500 mg daily) and vitamin D (400 to 800 IU daily) should be taken alongside Raloxifene therapy when dietary intake is insufficient.

Reduction of Invasive Breast Cancer Risk in High-Risk Postmenopausal Women

Raloxifene 60 mg is FDA-approved for the reduction of risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are at elevated risk of invasive breast cancer. High risk is defined as having one or more first-degree relatives with breast cancer, a prior breast biopsy demonstrating lobular carcinoma in situ or atypical hyperplasia, or a 5-year predicted breast cancer risk greater than 1.66%. In the MORE and CORE clinical trials, Raloxifene reduced the risk of all breast cancers by 62%, invasive breast cancer by 72%, and invasive estrogen receptor-positive breast cancer by 84% compared to placebo. It achieves this by blocking estrogen receptors in breast tissue, preventing estrogen from stimulating breast cancer cell growth and proliferation. It is recommended by NICE (UK) for this indication in eligible postmenopausal women and is prescribed for 5 years in this context.

Important: Raloxifene is not indicated for the treatment of established invasive breast cancer, nor does it reduce the risk of estrogen receptor-negative breast cancer.

Cholesterol and Lipid Profile Improvement

Clinical trials confirmed that Raloxifene 60 mg significantly reduces total cholesterol by 3 to 6% and LDL cholesterol by 4 to 10% without increasing triglycerides or HDL cholesterol. This beneficial lipid effect provides additional cardiovascular metabolic benefit in postmenopausal women who are at increased risk of cardiovascular disease due to declining estrogen.

Gynecomastia in Adolescent Males (Off-Label)

Raloxifene has been studied off-label for the treatment of pubertal gynecomastia in adolescent boys, with a small retrospective review demonstrating effectiveness. It is not licensed for this indication but may be prescribed under specialist medical supervision.

How Does Raloxifene 60 mg Work?

Raloxifene is a benzothiophene-derived SERM — structurally distinct from first-generation SERMs such as tamoxifen. It works by selectively binding to estrogen receptors (ER-alpha and ER-beta) throughout the body, but producing fundamentally different effects depending on the target tissue:

In bone tissue — estrogen agonist effect: Raloxifene binds to estrogen receptors in osteoblasts and osteoclasts, upregulating osteoprotegerin and suppressing RANKL-mediated osteoclastogenesis — the process by which osteoclasts (bone-resorbing cells) are activated. This reduces bone resorption, maintains bone mineral density, and normalises calcium homeostasis through reduced urinary calcium losses.

In breast tissue — estrogen antagonist effect: Raloxifene binds to estrogen receptors in breast cells but produces an antagonist conformation — blocking estrogen from attaching to and activating these receptors. This prevents estrogen from stimulating the growth of estrogen receptor-positive breast cancer cells without affecting normal breast tissue structure.

In uterine tissue — neutral to antagonist effect: Unlike tamoxifen, which has estrogen-agonist effects on the uterine endometrium and increases the risk of endometrial hyperplasia and endometrial cancer, Raloxifene does not stimulate the endometrium. Clinical trials confirmed that Raloxifene does not cause endometrial thickening, spotting, menstrual-type bleeding, or increase the risk of endometrial or ovarian cancer — a significant clinical advantage.

In liver and lipid metabolism — estrogen agonist effect: Raloxifene acts as an estrogen agonist in hepatic lipid metabolism, lowering total cholesterol and LDL cholesterol levels, modifying cardiovascular risk markers including fibrinogen and lipoprotein A, and increasing HDL2-C.

Dosage and How to Take Raloxifene 60 mg

Recommended Dose

One Raloxifene 60 mg tablet taken orally once daily. The tablet may be taken at any time of day, with or without food. Take at the same time each day to maintain consistency.

Step 1 – Take Once Daily Swallow the tablet whole with a full glass of water. Do not crush or chew. It may be taken with or without a meal, at whatever time of day suits your routine best.

Step 2 – Take Calcium and Vitamin D If your daily dietary intake of calcium and vitamin D is insufficient, take supplemental calcium (targeting 1,500 mg of elemental calcium per day) and vitamin D (400 to 800 IU per day) alongside Raloxifene as directed by your physician.

Step 3 – Take Consistently Every Day Continue taking Raloxifene even when you feel well. Bone protection is built over time with consistent daily use. Do not stop taking Raloxifene without consulting your doctor.

Step 4 – Missed Dose If a dose is missed, take it as soon as you remember on the same day. If it is the following day, skip the missed dose and resume your regular schedule. Do not double dose.

Step 5 – Pre-Surgery Precaution Stop taking Raloxifene at least 3 days before any planned major surgery or any period of extended immobility such as long-haul travel involving prolonged sitting. Restart only once you are fully mobile again, under your doctor's guidance.

Important — Travel Precaution: When travelling and taking Raloxifene, avoid sitting still for long periods. Walk regularly during long flights or car journeys to reduce the risk of blood clot formation in the legs.

Raloxifene vs Tamoxifen – Key Clinical Differences

Both Raloxifene and Tamoxifen are SERMs used in postmenopausal women, and both reduce breast cancer risk. However, they have important clinical differences:

• Endometrial safety: Raloxifene does not stimulate the uterine endometrium and does not increase the risk of endometrial cancer. Tamoxifen has estrogen-agonist effects on the uterus and is associated with increased endometrial cancer risk
• Breast cancer indication: Tamoxifen is approved for both the treatment and prevention of breast cancer. Raloxifene is approved only for the risk reduction of invasive breast cancer — not its treatment
• Bone protection: Both provide bone protection, but Raloxifene's bone efficacy and safety profile make it the preferred SERM choice specifically for osteoporosis management
• Hot flashes: Both may cause or worsen hot flashes. Clinical reports suggest Raloxifene may be better tolerated in this respect than Tamoxifen in some patients
• Uterine bleeding: Raloxifene does not cause vaginal spotting or menstrual-type bleeding. Any bleeding while on Raloxifene is unexpected and must be evaluated by a doctor immediately

Contraindications – Who Should Not Take Raloxifene 60 mg?

Raloxifene 60 mg is contraindicated in:

• Women with a current or past history of venous thromboembolism (VTE) — including deep vein thrombosis (DVT), pulmonary embolism, or retinal vein occlusion
• Women with active or history of stroke or transient ischaemic attack (TIA)
• Women with atrial fibrillation or uncontrolled hypertension due to increased stroke severity risk
• Premenopausal women — Raloxifene is not approved for use before menopause
• Pregnant or breastfeeding women — Raloxifene can cause fetal harm and must not be used in pregnancy
• Women with severe hepatic impairment — Raloxifene is primarily metabolised in the liver and plasma concentrations are significantly elevated in hepatic impairment
• Women currently undergoing active treatment for breast or endometrial cancer — safety in this context has not been established
• Women receiving concomitant systemic estrogen therapy — the safety of combined use has not been established

Drug Interactions

Inform your doctor and pharmacist of all medications you are taking. Key interactions include:

Cholestyramine and anion exchange resins: Co-administration significantly reduces Raloxifene absorption and enterohepatic cycling by up to 60%. Do not take Raloxifene with cholestyramine or other bile acid sequestrants.

Warfarin: Raloxifene may modestly reduce prothrombin time. INR monitoring is recommended when initiating Raloxifene in women on warfarin anticoagulation.

Systemic estrogens: The concomitant use of Raloxifene with systemic estrogen preparations is not recommended as safety has not been established.

NSAIDs, aspirin, paracetamol, antibiotics, antihistamines, and benzodiazepines: Clinical trials confirmed no significant pharmacokinetic interactions between Raloxifene and these commonly co-administered medications.

Ampicillin: May reduce peak Raloxifene plasma concentration but does not affect overall bioavailability significantly.

Possible Side Effects

Raloxifene 60 mg is generally well tolerated. Side effects reported in clinical trials include:

• Hot flashes — the most commonly reported side effect; occurs in approximately 1 in 4 patients on Raloxifene
• Leg cramps — particularly in the calf muscles
• Peripheral oedema — swelling of the feet, ankles, or lower legs
• Joint pain or flu-like symptoms
• Headache
• Nausea or gastrointestinal discomfort

Serious side effects requiring immediate medical attention:

• Leg pain, warmth, redness, or swelling in one leg — signs of deep vein thrombosis (DVT)
• Sudden chest pain or difficulty breathing — signs of pulmonary embolism
• Sudden numbness or weakness on one side of the body, slurred speech, or vision changes — signs of stroke
• Sudden changes in vision — signs of retinal vein thrombosis
• Any unexpected vaginal bleeding — must be investigated immediately as it is not expected with Raloxifene

Storage Instructions

Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Excursions between 15 and 30 degrees Celsius are permitted for short periods. Store in a tightly closed, light-resistant container. Keep out of reach of children. Do not use after the expiry date printed on the packaging.

Frequently Asked Questions

What is Raloxifene 60 mg used for? Raloxifene 60 mg is FDA-approved for the treatment and prevention of postmenopausal osteoporosis, and for reducing the risk of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk of breast cancer.

Is Raloxifene the same as Evista? Yes. Raloxifene 60 mg is the generic equivalent of Evista (Eli Lilly). Both contain the same active ingredient — Raloxifene Hydrochloride 60 mg — and deliver the same clinical efficacy at a significantly lower cost.

How does Raloxifene protect bones? Raloxifene acts as an estrogen agonist in bone tissue, reducing bone resorption, preserving bone mineral density, and reducing the risk of vertebral fractures. It does not prevent hip fractures.

Does Raloxifene increase the risk of endometrial cancer like Tamoxifen? No. Unlike Tamoxifen, Raloxifene does not stimulate the uterine endometrium. Clinical trials confirmed no increased risk of endometrial hyperplasia, uterine bleeding, or endometrial cancer with Raloxifene use.

How long do I need to take Raloxifene? For breast cancer risk reduction, it is typically prescribed for 5 years. For osteoporosis, long-term use is common with no defined maximum duration, subject to a formal treatment review approximately every 5 years.

Can Raloxifene treat hot flashes? No. Raloxifene does not treat menopausal hot flashes and may actually cause or worsen them. It is not a hormone replacement therapy.

Do you ship Raloxifene 60 mg to USA, UK, and UAE? Yes. We provide discreet, secure international shipping to the United States, United Kingdom, UAE (Dubai, Abu Dhabi), Saudi Arabia, Australia, and India.

Is a prescription required? Yes. Raloxifene 60 mg is a prescription medication. Always consult a qualified gynaecologist, endocrinologist, or healthcare provider before beginning therapy.

Medically Reviewed Content This product description has been written in accordance with clinical pharmacology guidelines and publicly available pharmaceutical references including the FDA-approved prescribing information for Evista (Eli Lilly), the UK Electronic Medicines Compendium (EMC) Summary of Product Characteristics, DailyMed (NIH), NCBI StatPearls Raloxifene monograph, MedlinePlus drug information, Bone Health and Osteoporosis Foundation (BHOF) patient guide, Cancer Research UK raloxifene treatment information, and the American Academy of Family Physicians (AAFP) Raloxifene clinical review. Always consult a licensed healthcare provider before starting or changing any osteoporosis or hormonal therapy.